Analyst picks & changes

Chiron Corp.

(CHIR)

Business: Biopharmaceuticals

Morgan Stanley's Hecht raised his 12-month price target to $93 from $83, after the Emeryville, Calif., company reported better than expected second quarter results. EPS of 2

Read the full 327 word article

How to gain access

Continue reading with a
two-week free trial.